コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ia (163 trials [79%] on acne and 43 [21%] on rosacea).
2 tract infection, chest pain, back pain, and rosacea).
3 including atopic dermatitis, psoriasis, and rosacea.
4 ilation and the inflammation associated with rosacea.
5 ow-up, we identified 5,462 incident cases of rosacea.
6 ent thinking about the parent disorder, acne rosacea.
7 antimicrobial peptide LL-37 is a hallmark of rosacea.
8 tory skin diseases, including dermatitis and rosacea.
9 known about use of PROMs in RCTs on acne and rosacea.
10 nder TRPV4 a translational-medical target in rosacea.
11 ciation between smoking and risk of incident rosacea.
12 e development of new treatments for acne and rosacea.
13 lammation in murine models of dermatitis and rosacea.
14 pro-inflammatory and vasodilative signals in rosacea.
15 ol for assessing gland involvement in ocular rosacea.
16 owest proportion of erythematotelangiectatic rosacea.
17 and impaired muscle contraction function in rosacea.
18 en different measures of smoking and risk of rosacea.
19 comes assessed during intervention trials of rosacea.
20 wenty-four patients had associated cutaneous rosacea.
21 nd 7.62 (95% CI, 6.78-8.57) in patients with rosacea.
22 lation and 4.99 (4.32-5.76) in patients with rosacea.
23 = 1.14-1.37), respectively, in patients with rosacea.
24 42.2 [16.5] years) were registered as having rosacea.
25 individuals, including 82,439 patients with rosacea.
26 to enhanced sensitivity to UVB radiation in rosacea.
27 influence of environmental factors affecting rosacea.
28 etinoin, are associated with improvements in rosacea.
29 and expectations of individuals affected by rosacea.
30 uture studies to better understand and treat rosacea.
31 eutrophils reach a maximum in papulopustular rosacea.
32 n underestimated hallmark in all subtypes of rosacea.
33 therapy, and topical cyclosporine for ocular rosacea.
34 owed by a crescendo pattern toward phymatous rosacea.
35 urveyed regarding risk factors implicated in rosacea.
36 entarium for recalcitrant cases of childhood rosacea.
37 es such as psoriasis, atopic dermatitis, and rosacea.
38 as a critical element in the pathogenesis of rosacea.
39 cal protease involved in the pathogenesis of rosacea.
40 icacy and fewest adverse events for treating rosacea?
41 vs. 0.43 without disease; P < 0.001), facial rosacea (0.47 vs. 0.43; P = 0.002), rheumatoid arthritis
42 1.88, 1.96)], psoriasis [2.62 (2.54, 2.69)], rosacea [2.84 (2.78, 2.90)], hidradenitis suppurativa [1
43 timates being psoriasis [3.52 (3.42, 3.61)], rosacea [2.85 (2.79, 2.92)], and alopecia areata [2.81 (
44 , contact lens wear in the setting of ocular rosacea (3 eyes), benzalkonium chloride toxicity (2 eyes
45 7] years) and 184 of the 68372 patients with rosacea (67.3% women; mean [SD] age, 42.2 [16.5] years).
47 have been implicated in the pathogenesis of rosacea, a disorder treated by the use of low-dose doxyc
48 e by 2 of the authors, using the search term rosacea, according to the Preferred Reporting items for
49 ection of the cathelicidin peptides found in rosacea, addition of SCTE, and increasing protease activ
50 ease in patients classified as having ocular rosacea (adjusted IRR, 2.03 [95% CI, 1.67-2.48]), and te
52 trend = 0.003) and with a decreased risk of rosacea among current smokers (P for trend < 0.0001).
53 king was associated with an elevated risk of rosacea among past smokers (P for trend = 0.003) and wit
56 is, France) included 42 children with ocular rosacea and 44 healthy volunteers (median ages of 10 and
57 eligible for analysis; of these, 68 372 had rosacea and 5 416 538 constituted the reference populati
58 ons, we investigated the association between rosacea and dementia, including AD in Danish registers.
62 ings suggest that MRGPRX2/B2 participates in rosacea and that beta-arrestin 2 contributes to its path
64 nformation on history of clinician-diagnosed rosacea and year of diagnosis was collected in 2005.
65 in the enhanced sensitivity of patients with rosacea, and observed that the epidermis of patients wit
66 pport the concept of a genetic component for rosacea, and provide candidate targets for future studie
67 th regards to etiology and therapy of ocular rosacea, and will also examine current thinking about th
69 ssed forms of cathelicidin peptides found in rosacea are different from those present in normal indiv
71 er smoking, we observed an increased risk of rosacea associated with past smoking (multivariable-adju
72 ndividuals and patients with dry eye who had rosacea-associated meibomian gland disease (MGD) or Sjog
73 and likely contribute to the pathogenesis of rosacea, atopic dermatitis, allergic contact dermatitis,
74 in all except 1 patient who had significant rosacea blepharokeratoconjunctivitis, whose BCVA remaine
75 ea patients have signs or symptoms of ocular rosacea, but few cases were confirmed by an ophthalmolog
76 ) has been implicated in the pathogenesis of rosacea, but the receptor involved and the mechanism of
77 ited to patients with a primary diagnosis of rosacea by a hospital dermatologist (n = 5964), the adju
78 ggest an explanation for the pathogenesis of rosacea by demonstrating that an exacerbated innate immu
79 discovery group of 22,952 individuals (2,618 rosacea cases and 20,334 controls) was analyzed, leading
81 tion of the immune system in all subtypes of rosacea, characterizing erythematotelangiectatic rosacea
82 (BP), and chronic atopic and chronic ocular rosacea cicatrizing conjunctivitis; and normal human ser
84 identified a final core set of 8 domains for rosacea clinical trials: ocular signs and symptoms; skin
89 found that skin biopsies from patients with rosacea display higher frequencies of MCs expressing MRG
90 cea, characterizing erythematotelangiectatic rosacea (ETR) already as a disease with significant infl
93 observed that the epidermis of patients with rosacea expressed higher amounts of Toll-like receptor 2
96 ormal control subjects, patients with ocular rosacea had a greater delay of tear fluorescein clearanc
97 We observed that dermal endothelial cells in rosacea had an increased expression of VCAM1 and hypothe
98 ecent articles on the pathogenesis of ocular rosacea have focused on the role of bacterial lipases, a
102 outcome was the proportion of patients with rosacea in each of the 4 major subtype groups defined by
103 Recent articles on the prevalence of ocular rosacea in patients with acne rosacea suggested that bet
104 proteins, were significantly associated with rosacea in the discovery group and confirmed in the repl
105 ted using the search terms acne vulgaris and rosacea in the following databases: MEDLINE through PubM
107 fluid obtained from 13 patients with ocular rosacea (including 1 patient with recurrent epithelial e
108 The activated form of NFKB is enriched in rosacea, indicating a role for this pathway in the patho
109 ng these antibiotics exclusively for acne or rosacea (indications that could be risk factors for brea
110 fective anti-inflammatory strategy to reduce rosacea inflammation by restricting pathogenic T-cell in
123 reporting of outcomes in clinical trials of rosacea is impeding and likely preventing accurate data
128 A-DRA and BTNL2 expression in papulopustular rosacea lesions from six individuals, including one with
131 d the molecular mechanisms of LL-37-mediated rosacea-like inflammation in an in vitro model of normal
136 Elevated gelatinase B activity in ocular rosacea may be involved in the pathogenesis of the irrit
139 antly more important in children with ocular rosacea (mean meiboscore 2.1 +/- 1.36) than in healthy v
140 antly more important in children with ocular rosacea (mean meiboscore 2.1 1.36) than in healthy volun
142 lytic cathelicidin fragment LL37 in a murine rosacea model and that TRPV4 loss of function attenuates
144 riant of NFKB (pNFKB) in eyelid specimens of rosacea (n = 12) and normal, healthy tissue (n = 12).
146 leotide polymorphisms (SNPs) associated with rosacea, one of which replicated in a new group of 29,48
147 s with a hospital dermatologist diagnosis of rosacea only, the adjusted HRs of dementia and AD were 1
152 cea suggested that between 6 and 18% of acne rosacea patients have signs or symptoms of ocular rosace
153 he mean ratios of pNFKB:NFKB for control and rosacea patients measured 0.58 (standard deviation = 0.8
155 nts and 39.3 (standard deviation = 16.9) for rosacea patients, and the difference between the 2 group
156 e immunohistochemistry on facial biopsies of rosacea patients, classified according to their clinical
160 (110) included; PROM use was more common in rosacea RCTs (67% [n = 29]) compared with acne RCTs (50%
162 ogy, etiology, and optimal therapy of ocular rosacea remain to be determined, and will require a more
167 re were 233 identical twin pairs with a mean rosacea score of 2.46 and 42 fraternal twin pairs with a
168 nmelanoma skin cancer, dermatophytosis, acne rosacea, seborrheic keratosis, or warts; 74.1% of the su
172 a were confirmed on erythematotelangiectatic rosacea subjects who showed a decrease in matrix metallo
174 and meta-analysis, differences were found in rosacea subtypes by patient sex and by continent of orig
178 ence of ocular rosacea in patients with acne rosacea suggested that between 6 and 18% of acne rosacea
181 Although environmental factors influence rosacea, the genetic basis of rosacea is not established
182 y improve the usefulness of future trials of rosacea therapies by enabling meta-analyses and other co
183 To our knowledge, this is the first study on rosacea to formally define genetic and environmental con
184 rm when BPO drug products, used for acne and rosacea treatment, are incubated at body temperature and
186 o presented with severe ocular and cutaneous rosacea unresponsive to oral doxycycline, oral isotretin
187 fficacy and safety of therapies for acne and rosacea vs any comparator were eligible for inclusion.
188 te ratio (95% CI) of glioma in patients with rosacea was 1.36 (1.18-1.58) in our primary analysis.
190 .7% (95% CI, 51.4%-62.0%), of papulopustular rosacea was 43.2% (95% CI, 38.8%-47.6%), of phymatous ro
191 ooled proportion of erythematotelangiectatic rosacea was 56.7% (95% CI, 51.4%-62.0%), of papulopustul
192 as 43.2% (95% CI, 38.8%-47.6%), of phymatous rosacea was 7.4% (95% CI, 6.1%-8.9%), and of ocular rosa
198 Erythematotelangiectatic and papulopustular rosacea were the most prevalent subtypes, but data shoul
199 cells are increased in all three subtypes of rosacea, whereas neutrophils reach a maximum in papulopu
202 h as acne, atopic dermatitis, psoriasis, and rosacea with an imbalance of the microflora even in the
203 ition of metronidazole (a drug used to treat rosacea) within the skin and proximal to its site of pha